Arch Therapeutics Receives Clearance to Initiate Clinical Trial in Europe

Achieves Milestone in CE Mark Evaluation Process for the AC5 Surgical Hemostatic Device(TM) FRAMINGHAM, MA ARTH, (Marketwired Dec 16, 2015) Arch Therapeutics, Inc. (OTCQB: ARTH) ( Arch or the Company ), a life sciences company and developer of the AC5 Surgical Hemostatic Device™ ( AC5™ ), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has received clearance to initiate a human clinical trial from a regulatory authority in Western Europe. The randomized controlled single-blind investigation is designed to assess safety and performance of AC5™ in bleeding wounds created during the course of a dermatological procedure in fewer than 50 patients. The endpoints include product related adverse effects, with a planned patient follow-up assessment 30 days following the procedure, and time to hemostasis. A portion of the patients will be taking a therapeutics dose of an antithrombotic medication (commonly

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: